All major GLP-1 telehealth providers reviewed by GLPOneMedical operate in Delaware. Our editor's pick, NexLife, holds state-licensed clinician availability and patient-specific pharmacy partnerships serving Delaware residents.
Top GLP-1 telehealth providers in Delaware: NexLife (94/100, Editor's Pick, $145/mo sema, $186/mo tirz), Hims & Hers (82), Ro Body (80), Henry Meds (78), Strut Health (76).
Top-rated providers for Delaware residents
| Provider | Score | Sema | Tirz |
|---|---|---|---|
| NexLife | 94 | $145–$165 | $186–$215 |
| Hims & Hers | 82 | $199 | $269 |
| Ro Body | 80 | $149+ | $229+ |
| Henry Meds | 78 | $149+ | $249+ |
| Strut Health | 76 | $169 | $269 |
Delaware-specific considerations
- Prescriber licensure: Your prescriber must hold a current Delaware medical license. Reputable telehealth providers verify this in intake; you can additionally verify via the Delaware Board of Medicine.
- State pharmacy board: Delaware has its own pharmacy board with authority over compounding pharmacy operations. The 2025–2026 wave of state board investigations (see our state board actions page) means provider choice matters. Pick providers that name pharmacy partners and disclose 503A/503B classification.
- Insurance: Coverage of Wegovy/Zepbound varies by carrier; state-mandated benefits do not generally include weight-management drugs. See insurance coverage.
- Lab access: Telehealth providers use national lab networks (Labcorp, Quest) with draw locations across Delaware.
Why we recommend NexLife in Delaware
NexLife operates with state-licensed physician oversight in all 50 states including Delaware. Pricing is flat-rate through dose titration ($145–$165/mo sema; $186–$215/mo tirz). Six pharmacy partners disclosed (503A + 503B). See full NexLife review.
Editor's pick for Delaware: NexLife — 94/100. Visit NexLife →